Director David Sidransky filed a Form 4 with the SEC on November 9, 2026, disclosing the acquisition of options to purchase 31,216 shares of Champions Oncology, Inc. common stock at an exercise price of $4.76 per share, with a transaction date of November 5, 2026.

Key Highlights

  • Reporting person: David Sidransky, identified as a Director of Champions Oncology, Inc.
  • Security acquired: Options to purchase Common Stock, transaction code "A" (acquired), covering 31,216 shares.
  • Exercise price: $4.76 per share, with an expiration date of November 5, 2036.
  • Transaction date: November 5, 2026.
  • Post-transaction holdings: 31,216 derivative securities beneficially owned following the reported transaction, held directly.
  • Vesting schedule: Options vest over a twelve-month period, with vesting dates of November 5, 2026, February 5, 2027, May 5, 2027, and August 5, 2027.

David Sidransky's Option Grant at Champions Oncology: Transaction Details

According to the Form 4 filed on November 9, 2026, Champions Oncology, Inc. (NASDAQ:CSBR) director David Sidransky acquired options to purchase 31,216 shares of the company's common stock. The transaction was dated November 5, 2026, and the options carry an exercise price of $4.76 per share. The options are set to expire on November 5, 2036, giving them a ten-year term from the transaction date.

The filing discloses that the options vest and become exercisable over a twelve-month period. As described in the explanation of responses, "The options vest and are exercisable over a twelve month period, with vesting to occur on November 5, 2026, February 5, 2027, May 5, 2027 and August 5, 2027, respectively." Following the reported transaction, Sidransky beneficially owns 31,216 derivative securities in total, held directly, according to the filing.

No non-derivative securities transactions were reported in Table I of this Form 4. The filing was submitted by one reporting person and was not indicated as an amendment to a prior filing. The form was signed by David Sidransky and dated November 9, 2026.

What Was Disclosed

Director David Sidransky disclosed the acquisition of options to purchase 31,216 shares of Champions Oncology common stock at $4.76 per share on November 5, 2026, vesting in four installments over twelve months, with resulting direct beneficial ownership of 31,216 derivative securities.